RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kangmei Pharmaceutical Co Stock

Kangmei Pharmaceutical Co EBIT 2024

Kangmei Pharmaceutical Co EBIT

172.03 M CNY

Ticker

600518.SS

ISIN

CNE0000017M1

In 2024, Kangmei Pharmaceutical Co's EBIT was 172.03 M CNY, a -117.02% increase from the -1.01 B CNY EBIT recorded in the previous year.

The Kangmei Pharmaceutical Co EBIT history

YEAREBIT (undefined CNY)
20230.17
2022-1.01
2021-4.02
2020-23.46
2019-1.83
20182.49
20173.92
20164.58
20153.57
20143.04
20132.48
20121.96
20111.3
20100.85
20090.6
20080.33
20070.24
20060.17
20050.12
20040.12

Kangmei Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Kangmei Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kangmei Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kangmei Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kangmei Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kangmei Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kangmei Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kangmei Pharmaceutical Co’s growth potential.

Kangmei Pharmaceutical Co Revenue, EBIT and net profit per share

DateKangmei Pharmaceutical Co RevenueKangmei Pharmaceutical Co EBITKangmei Pharmaceutical Co Net Income
20234.87 B undefined172.03 M undefined102.52 M undefined
20224.18 B undefined-1.01 B undefined-2.69 B undefined
20214.15 B undefined-4.02 B undefined7.92 B undefined
20205.41 B undefined-23.46 B undefined-27.74 B undefined
201911.45 B undefined-1.83 B undefined-4.66 B undefined
201817.07 B undefined2.49 B undefined374 M undefined
201717.58 B undefined3.92 B undefined2.15 B undefined
201621.64 B undefined4.58 B undefined3.34 B undefined
201518.07 B undefined3.57 B undefined2.76 B undefined
201415.95 B undefined3.04 B undefined2.29 B undefined
201313.36 B undefined2.48 B undefined1.88 B undefined
201211.17 B undefined1.96 B undefined1.44 B undefined
20116.08 B undefined1.3 B undefined1.01 B undefined
20103.31 B undefined853 M undefined716 M undefined
20092.38 B undefined598 M undefined502 M undefined
20081.73 B undefined332 M undefined295 M undefined
20071.29 B undefined240 M undefined179 M undefined
2006826 M undefined167 M undefined100 M undefined
2005585 M undefined120 M undefined73 M undefined
2004553 M undefined115 M undefined71 M undefined

Kangmei Pharmaceutical Co stock margins

The Kangmei Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kangmei Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kangmei Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kangmei Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Kangmei Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kangmei Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kangmei Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kangmei Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kangmei Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kangmei Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kangmei Pharmaceutical Co Margin History

Kangmei Pharmaceutical Co Gross marginKangmei Pharmaceutical Co Profit marginKangmei Pharmaceutical Co EBIT marginKangmei Pharmaceutical Co Profit margin
202322.22 %3.53 %2.1 %
20227.86 %-24.18 %-64.32 %
2021-11.26 %-96.82 %190.68 %
2020-375.33 %-433.56 %-512.49 %
20197.42 %-15.99 %-40.72 %
201831.28 %14.58 %2.19 %
201738.07 %22.3 %12.23 %
201629.42 %21.16 %15.43 %
201528.05 %19.75 %15.26 %
201425.97 %19.07 %14.33 %
201325.9 %18.54 %14.07 %
201224.95 %17.56 %12.91 %
201129.73 %21.3 %16.53 %
201035.96 %25.78 %21.64 %
200933.11 %25.16 %21.12 %
200826.69 %19.22 %17.08 %
200725.73 %18.55 %13.83 %
200628.81 %20.22 %12.11 %
200530.77 %20.51 %12.48 %
200430.38 %20.8 %12.84 %

Kangmei Pharmaceutical Co Aktienanalyse

What does Kangmei Pharmaceutical Co do?

Kangmei Pharmaceutical Co. Ltd is a Chinese company that was founded in 1997. It is headquartered in the city of Lianyungang in the Jiangsu province and has been listed on the Shanghai Stock Exchange since 2001. With a market capitalization of over 15 billion US dollars, it is one of the leading pharmaceutical companies in the country. The company's business model is based on the development, production, and distribution of pharmaceutical products and medical devices. It is divided into several divisions, including drugs for colds, diabetes, cancer, and other diseases, dietary supplements, contrast agents for X-rays, as well as medical devices such as infusion pumps, blood pressure monitors, and ultrasound machines. Kangmei has focused heavily on the domestic market in recent years and is present in all provinces of China. It operates over 30 subsidiaries throughout the country and has more than 10,000 employees. The company is committed to improving healthcare in China and developing innovative products for the domestic market. One of Kangmei's most well-known drugs is "Ganmaoling Granule," a traditional Chinese medicine for treating colds and flu. It has been in production for over 30 years and is very popular in China. Kangmei also produces various drugs for the treatment of diabetes, including insulin preparations and oral medications. Another important area for Kangmei is the development of cancer drugs. The company specializes in researching and developing innovative therapies for various types of cancer. It has introduced several products to the market that can be used in the treatment of lung cancer, breast cancer, and other tumors. In addition to its pharmaceutical products, Kangmei has also developed a range of dietary supplements, such as "Qingkailing Capsules," which are made from natural ingredients and are intended to strengthen the immune system. These products are very popular in China and also contribute to Kangmei's diversification of its business operations. Kangmei has also specialized in the production of medical devices. It has developed a wide range of products such as infusion pumps, dialysis machines, and ultrasound devices. These devices are in high demand in China and other countries around the world, such as Africa and Latin America. Overall, Kangmei has established a strong presence in the Chinese pharmaceutical and medical market and is well-positioned to benefit from the strong growth of the healthcare sector in China. The company focuses on innovation and invests heavily in research and development of new products. It aims to play a leading role in the Chinese healthcare industry while contributing to the improvement of healthcare services. Kangmei Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Kangmei Pharmaceutical Co's EBIT

Kangmei Pharmaceutical Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Kangmei Pharmaceutical Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Kangmei Pharmaceutical Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Kangmei Pharmaceutical Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Kangmei Pharmaceutical Co stock

How much did Kangmei Pharmaceutical Co achieve in EBIT for the current year?

In the current year, Kangmei Pharmaceutical Co has achieved an EBIT of 172.03 M CNY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Kangmei Pharmaceutical Co.

How has the EBIT of Kangmei Pharmaceutical Co developed in recent years?

The EBIT of Kangmei Pharmaceutical Co has increased by -117.023% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Kangmei Pharmaceutical Co?

The EBIT of Kangmei Pharmaceutical Co is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Kangmei Pharmaceutical Co pay?

Over the past 12 months, Kangmei Pharmaceutical Co paid a dividend of 0.02 CNY . This corresponds to a dividend yield of about 0.87 %. For the coming 12 months, Kangmei Pharmaceutical Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of Kangmei Pharmaceutical Co?

The current dividend yield of Kangmei Pharmaceutical Co is 0.87 %.

When does Kangmei Pharmaceutical Co pay dividends?

Kangmei Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of June, July, August, September.

How secure is the dividend of Kangmei Pharmaceutical Co?

Kangmei Pharmaceutical Co paid dividends every year for the past 0 years.

What is the dividend of Kangmei Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kangmei Pharmaceutical Co located?

Kangmei Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kangmei Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kangmei Pharmaceutical Co from 8/28/2019 amounting to 0.024 CNY, you needed to have the stock in your portfolio before the ex-date on 8/28/2019.

When did Kangmei Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 8/28/2019.

What was the dividend of Kangmei Pharmaceutical Co in the year 2023?

In the year 2023, Kangmei Pharmaceutical Co distributed 0 CNY as dividends.

In which currency does Kangmei Pharmaceutical Co pay out the dividend?

The dividends of Kangmei Pharmaceutical Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kangmei Pharmaceutical Co

Our stock analysis for Kangmei Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kangmei Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.